Health CareMedical Equipment and Services
  • Price (USD)113.24
  • Today's Change0.80 / 0.71%
  • Shares traded4.51m
  • 1 Year change-3.87%
  • Beta0.7128
Data delayed at least 15 minutes, as of May 20 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.

  • Revenue in USD (TTM)44.51bn
  • Net income in USD7.73bn
  • Incorporated1900
  • Employees113.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttps://www.abbott.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABT:NYQ since
Walk Vascular LLCDeal completed02 Sep 202102 Sep 2021Deal completed-11.11%--
Data delayed at least 15 minutes, as of May 20 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Boston Scientific Corporation12.16bn754.00m56.45bn41.00k75.173.3730.474.640.52530.52538.4711.710.38472.436.96296,634.202.563.262.914.0068.5869.406.658.030.77875.910.35730.0019.927.23956.5223.201.75--
Edwards Lifesciences Corp5.36bn1.54bn58.67bn15.70k38.6810.0335.0210.952.442.448.499.410.68531.678.76341,216.6019.6815.9922.1618.9576.5875.1128.7223.632.64--0.09250.0019.2912.0482.5521.428.69--
Becton Dickinson and Co20.03bn1.83bn71.59bn75.00k39.602.9217.443.576.346.3469.3786.030.36523.539.06267,080.003.502.613.932.9645.8146.639.597.491.048.510.431872.7918.2910.16161.0215.4511.394.69
Intuitive Surgical, Inc.5.91bn1.64bn78.30bn9.79k48.626.4738.9913.264.494.4916.1133.720.46842.997.57603,053.2013.1814.1214.3915.6868.8468.8328.1529.384.63--0.000.0031.0116.1060.7218.2245.67--
Stryker Corporation17.43bn2.02bn87.16bn46.00k43.755.7929.345.005.275.2745.5739.780.50091.856.22378,913.005.796.736.587.9562.9164.7511.5613.161.18--0.483842.3919.218.6024.703.901.3911.20
Medtronic PLC31.79bn4.91bn137.84bn90.00k28.292.6318.054.343.633.6323.5139.140.33622.225.96353,166.705.224.775.905.3668.4668.5115.5314.962.1021.710.32360.934.160.8752-25.94-0.21575.318.83
Abbott Laboratories44.51bn7.73bn196.88bn113.00k25.965.5617.654.424.334.3324.9420.220.60653.446.71393,929.2010.535.5912.746.5757.1457.1817.3511.611.4019.640.324263.2224.4715.6157.2446.0810.9511.60
Thermo Fisher Scientific Inc.41.12bn7.60bn215.59bn130.00k28.685.2620.605.2419.2019.20103.78104.630.51834.325.43316,330.809.627.4910.958.5748.3747.2818.5616.381.1023.360.44716.7721.7116.5021.1830.7041.5510.76
Data as of May 20 2022. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

31.85%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2022144.27m8.18%
BlackRock Fund Advisorsas of 31 Mar 202286.38m4.90%
Capital Research & Management Co. (Global Investors)as of 31 Dec 202184.13m4.77%
SSgA Funds Management, Inc.as of 31 Dec 202174.32m4.22%
Capital Research & Management Co. (International Investors)as of 31 Dec 202152.40m2.97%
Geode Capital Management LLCas of 31 Mar 202228.55m1.62%
Massachusetts Financial Services Co.as of 31 Mar 202225.88m1.47%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202225.37m1.44%
Polen Capital Management LLCas of 31 Mar 202222.42m1.27%
Morgan Stanley Investment Management Ltd.as of 31 Mar 202217.85m1.01%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.